-Newly reported data on sixth and final patient in cohort further confirms previously announced improvements in hand and arm function following dosing-

 

FREMONT, Calif., March 21, 2017 -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, reported that including the sixth and final patient in the AIS-A 10 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical trial has further confirmed previously-announced motor function improvements at 6-months following administration of AST-OPC1. 

The patent extends Pulmatrix's broad protection for its innovative technology to Europe

 

LEXINGTON, Mass., March 21, 2017 -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key patent from the European Union.

 

"This new patent shows our continued ability to obtain patents that protect our unique iSPERSE inhaled drug technology—and that also reflect the advances we are making in drug delivery," said Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. "It gives us a strong intellectual property protection position in Europe as we move forward with our drug candidates for COPD, fungal infections, and other diseases."

Mr. Paul Baehr reports

 

IBEX REPORTS RESULTS FOR THE SECOND QUARTER AND THE SIX MONTHS ENDED JANUARY 31, 2017

 

IBEX Technologies Inc. has released its financial results for the six months ended Jan. 31, 2017.

 

"The second quarter of fiscal 2017 was a very positive quarter for the company with sales increasing 35 per cent over year ago and 27 per cent over the previous quarter," said Paul Baehr, IBEX president and chief executive officer. "Net earnings increased 114 per cent over the same quarter year ago and by 113 per cent over the previous quarter. In addition, cash and cash equivalents have increased by 8 per cent during the quarter despite the investment in our new fermentation facility.

NKTR-181 Significantly Reduced Pain in Patients with Moderate to Severe Chronic Low Back Pain

Primary Efficacy Endpoint Achieved (p=0.0019)

Analyst Conference Call and Webcast Today at 5:45 a.m. PDT/8:45 a.m. EDT

 

SAN FRANCISCO, March 20, 2017 / -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic.  NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.1  The U.S. Food and Drug Administration (FDA) has granted the investigational medicine NKTR-181 Fast Track designation for the treatment of moderate to severe chronic pain.